Short Interest in Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Decreases By 27.1%

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the target of a significant drop in short interest in February. As of February 27th, there was short interest totaling 2,586 shares, a drop of 27.1% from the February 12th total of 3,548 shares. Based on an average daily volume of 5,278 shares, the short-interest ratio is currently 0.5 days. Approximately 0.1% of the company’s stock are sold short. Approximately 0.1% of the company’s stock are sold short. Based on an average daily volume of 5,278 shares, the short-interest ratio is currently 0.5 days.

Fidelity Disruptive Medicine ETF Stock Up 2.2%

Shares of FMED stock traded up $0.52 during trading hours on Monday, hitting $24.58. 4,382 shares of the company’s stock traded hands, compared to its average volume of 7,964. The stock’s fifty day simple moving average is $26.43 and its two-hundred day simple moving average is $26.38. Fidelity Disruptive Medicine ETF has a 12-month low of $20.69 and a 12-month high of $29.07. The stock has a market cap of $56.53 million, a price-to-earnings ratio of 41.33 and a beta of 1.00.

Institutional Investors Weigh In On Fidelity Disruptive Medicine ETF

A number of institutional investors have recently modified their holdings of the stock. Jane Street Group LLC raised its position in shares of Fidelity Disruptive Medicine ETF by 0.8% in the 1st quarter. Jane Street Group LLC now owns 66,382 shares of the company’s stock worth $1,567,000 after purchasing an additional 499 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in Fidelity Disruptive Medicine ETF by 4.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 714,991 shares of the company’s stock valued at $19,712,000 after purchasing an additional 31,629 shares during the last quarter. BXM Wealth LLC purchased a new stake in Fidelity Disruptive Medicine ETF during the 4th quarter valued at about $243,000. Glass Jacobson Investment Advisors llc increased its stake in Fidelity Disruptive Medicine ETF by 44.0% during the 4th quarter. Glass Jacobson Investment Advisors llc now owns 1,260 shares of the company’s stock valued at $34,000 after purchasing an additional 385 shares in the last quarter. Finally, Vise Technologies Inc. purchased a new position in Fidelity Disruptive Medicine ETF in the fourth quarter worth about $234,000.

About Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.